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LIVER GROWTH FACTOR (LGF) was first described as an endogenous factor with mitogenic properties in liver (21) .
LGF is not detected in physiological conditions, but it increases in plasma in situations of hepato-biliary disorders, both in humans and rats (21, 24) . The chemical analysis of LGF obtained from human and rat plasma has revealed that it is a covalently bound albumin-bilirubin complex (24, 25) . The regenerative effects of LGF, initially described in hepato-biliary disorders (22, 23, 26) , have been recently extended to other diseases, such as Parkinson's disease (35, 52) , testicular degeneration (51) , and pulmonary fibrosis (47) .
LGF treatment also has cardiovascular effects as previously shown in rodent models of hypertension (62) and atherosclerosis (65) . We have previously demonstrated that treatment of spontaneously hypertensive rats (SHR) with LGF significantly reduced blood pressure, which was associated with a reduction in extracellular matrix (ECM) content and improvement of vasodilator function of conduit arteries (62) . An interesting aspect is that the cardiovascular effects of LGF treatment were achieved in very short time and low dose (4.5 g LGF/rat ip 2 times/wk during 2 wk) compared with classical antihypertensive treatments (1) .
Essential hypertension is characterized by increased peripheral vascular resistance, related to alterations in small artery structure and vasodilator function. Resistance artery narrowing, increased stiffness, and reduced vasodilator responses are found in patients with essential hypertension (1, 48, 55) as well as in rat models of the disease such as the SHR and the stroke-prone rats (2, 8, 13, 39) . These alterations are not only important for the progression of hypertension but are also predictors of cardiovascular events in hypertensive subjects (48, 55) . Hypertension is also associated with left ventricular hypertrophy (LVH), characterized by an increase in myocite size or cell number, fibrosis, intramyocardial artery (IMA) remodeling, and reduction of the vascular component (29, 44, 59) . These alterations contribute to an insufficient blood supply to the myocardium and favor the development of adverse cardiovascular events (31, 37, 43, 46) . Therefore, reversion of resistance artery remodeling (1) and LVH (9, 57) are key aims of antihypertensive therapy.
Our previous data on the rapid and specific antihypertensive and antifibrotic actions of LGF on SHR conduit vessels suggest that this factor could be a potential therapeutic agent in the treatment of hypertension and its complications. The aim of the present study has been to gain further insight in the regenerative cardiovascular actions of LGF treatment in SHR, assessing its effects on intramyocardial and mesenteric resistance arteries (MRA) and LVH. Furthermore, we have investigated if the restoration of arterial cell/ECM disbalance by this factor is linked to a mitogenic effect on vascular smooth muscle cells (VSMC), as previously described in other cell types (26, 35, 52) .
METHODS

Experimental Design
Six-month-old male SHR and age-matched normotensive control Wistar-Kyoto (WKY) rats, bred at the animal house of Universidad Autónoma de Madrid, were used. The rats were divided in the following experimental groups: vehicle-treated (SHR; WKY) and LGF-treated (SHR-LGF; WKY-LGF). We purified LGF as previously described (21, 27) . Treatment was carried out as follows: LGF (4.5 g/rat) or saline solution (vehicle) was injected intraperitoneally four times (days 0, 3, 6, and 9) . At day 12, the rats were weighed and anesthetized with pentobarbital sodium (50 mg/kg), and intra-arterial blood pressure was recorded. Thereafter, the rat was killed by exanguination, and the heart was obtained; the atria were excised, and the ventricles were weighted and paraffin-embedded. The mesenteric bed was also dissected and placed in cold saline solution, and several third-order branches of the mesenteric bed (MRA) were obtained. MRA segments were used to study structure and mechanics (pressure myography), vascular function (wire myograph), cell and elastin content, nitric oxide (NO) and superoxide anion bioavaliability (confocal microscopy), and collagen fiber content [optimal cutting temperature (OCT) compound embedding, sirius red staining, and polarized light microscopy]. VSMC derived from carotid arteries from our previous study (62) were used for cell culture studies. Other group of rats (WKY, SHR before and after LGF treatment) were used to study transthoracic echocardiography (TTE).
All procedures conformed to the Guidelines for the Care and Use of Laboratory Animals (NIH publication no. 85-23, revised in 1996), the Spanish legislation (RD 1201/2005), and were approved by the Ethics Review Board of Universidad Autonoma de Madrid.
Blood Pressure Measurements
Systolic and diastolic blood pressures (SBP and DBP, respectively) were measured in WKY, SHR, WKY-LGF, and SHR-LGF rats under anesthesia (50 mg/kg pentobarbital sodium ip), Briefly, a cannula was inserted in the right iliac artery and connected to a pressure transducer (Statham; Harvard Apparatus), and SBP and DBP were recorded in a PowerLab system (ADInstruments).
Cultured VSMC Study
VSMC cultures were obtained from carotid artery explants derived from WKY, SHR, WKY-LGF, and SHR-LGF rats (62) . Briefly, VSMC growing out of carotid artery explants were harvested by trypsinization and frozen in 20% FBS and 10% dimethyl sulfoxide in liquid nitrogen until use. The cells were evenly plated (20,000 cells/ dish) and cultured in Dulbeco's modified Eagle's medium with 10% FBS (vol/vol), 100 U/ml penicillin, and 100 mg/ml streptomycin and maintained at 37°C in a humidified atmosphere consisting of 5% CO 2 and 95% air. Thereafter, VSMC were directly plated on 4-cm 2 glass cover slips for bromodeoxyuridine (BrdU) incorporation and fibronectin deposition experiments. All of the experiments were performed in VSMC up to passage 3. At these low passages, all VSMC express smooth muscle cell ␣-actin (7).
BrdU incorporation. Proliferation was assessed in VSMC maintained in culture for 7 days by BrdU incorporation during the last 24 h, immunodetection, and hematoxylin to counterstain the cell nuclei, as described previously (7) . The following two experimental protocols were performed: 1) BrdU incorporation in VSMC cultures derived from SHR and WKY rats, some of which were incubated during the last 48 h with LGF (50 ng/ml) and 2) BrdU incorporation in VSMC cultures derived from SHR, WKY as well as SHR-LGF and WKY-LGF treated rats. The cover slips with the VSMC were mounted on a slide with Prolong mounting medium. From each culture, a minimum of 10 randomly selected images were captured with a light microscope (Leica DMBL) equipped with a charge-coupled device camera, using a ϫ40 objective. The number of BrdU-positive and multinucleated VSMC was quantified with Metamorph image analysis software.
Fibronectin deposition. Fibronectin was assessed in parallel VSMC cultures with a monoclonal antibody to fibronectin, fluorescein-conjugated species-specific secondary antibody, and DAPI (1:500 from stock 5 mg/ml) to counterstain nuclei, as previously described (7) . The cover slips with the VSMC were mounted on a slide with Prolong mounting medium. From each culture, a minimum of 10 randomly selected images were captured with a Leica SP2 confocal microscope (Leica Microsystems) at excitation 488 nm/emission 500 -560 (fluorescein, fibronectin) and excitation 405 nm and emission 410 -475 nm (DAPI, nuclei) with a ϫ40 objective. The amount of fibronectin deposited by the VSMC was quantified with Metamorph image analysis software as the average gray level/VSMC number.
MRA Studies
Third-order branches from the mesenteric bed from untreated WKY, SHR, and SHR-LGF were used. The size range of the arteries in unpressurized conditions was as follows: WKY ϭ 150 -218 m; SHR ϭ 150 -193 m; and SHR-LGF ϭ 145-180 m of internal diameter. WKY-LGF treated rats were not used for this study based on our previous (62) and present data on hemodynamic parameters, ventricular weight, and cellular proliferation study showing no effect of LGF treatment on the normotensive strain.
Pressure myography. MRA segments were mounted on a pressure myograph (model P100; Danish Myo-Tech), as previously described (13) . Briefly, the segment was mounted between two glass cannulas in zero Ca 2ϩ physiological salt solution (0Ca 2ϩ PSS) of the following composition in mmol/l: 115 NaCl, 4.6 KCl, 25 NaHCO3, 1.2 KH2PO4, 1.2 MgSO4, 0.01 EDTA, 11 glucose, and 10 EGTA, at 37°C and bubbled with a mixture of of 95% O2 and 5% CO2. Intraluminal pressure was increased at 20-mmHg intervals (3, 20, 40, 60, 80 , 100, 120, and 140 mmHg), and external and internal diameters were recorded at each pressure level with a video camera coupled to Myoview software. From these data, we calculated geometric parameters [wall thickness, wall cross-sectional area (CSA), and the wallto-lumen ratio] and mechanical parameters (incremental distensibility and ␤Ϫvalues derived from the stress-strain relationship). The use of passive (0Ca 2ϩ ) conditions allowed assessing true changes in vascular structure without the influence of vessel tone. At the end of the pressure curve, the segment was pressure-fixed at 70 mmHg with 4% paraformaldehyde (PFA) at 37°C for 60 min and stored at 4°C for confocal microscopy study.
Wire myography. MRA segments were mounted on a wire myograph (Multi Myograph System, model 610M; Danish Myo-tech) coupled to a Powerlab data acquisition system (AD-Instruments, Castle Hill, Australia) and studied as described (17) . Briefly, the vessel was mounted between the wires in PSS with calcium (12.5 mmol/l CaCl2) omitting EDTA and EGTA. The artery was then set to a normalized internal circumference of 0.9L100, which was considered the effective lumen diameter, which represents the basal tone of the artery. After an equilibration period, responses to 75 mmol/l KCl, acetylcholine (ACh, 10 Ϫ9 to 10 Ϫ5 mol/l), and sodium nitroprusside (SNP, 10 Ϫ9 to 10 Ϫ4 mol/l) were studied in segments precontracted with norepinephrine (10 Ϫ7 mol/l). All drugs were added after a plateau of the previous concentration was reached. The contribution of NO to ACh responses was tested by the inhibition caused by 20 min preincubation with the NO synthase (NOS) inhibitor N G -nitro-Larginine methyl ester (L-NAME, 10 Ϫ4 mol/l). The contribution of endothelium-derived hyperpolarizing factor (EDHF) to ACh responses was studied in vessels precontracted with KCl (40 mmol/l for 10 min). To determine the contribution of NO and EDHF to AChmediated relaxation and sensitivity, the area under the curve (AUC) and EC50 values were calculated using GraphPad Prism-4 (GraphPad software).
Confocal microscopy study of vascular wall components. Confocal microscopy was used to assess the content of elastin in the internal elastic lamina (IEL) and the cell number in the adventitia, media, and endothelium in the MRA segments previously pressure-fixed at 70 mmHg. IEL was studied as described (13) . Briefly, the pressure-fixed segments were mounted intact on a slide provided with a small well made of spacers to avoid vessel compression, filled with Fluoroguard (glycerol-antifade agent; Bio-Rad) mounting medium, and visualized with a Leica TCS SP2 confocal system (Leica Microsystems) at excitation 488 nm/emission 500 -560 nm, since elastin is autofluorescent at this wavelength (71) . Three randomly selected regions of the IEL were studied for quantitative analysis. In each, serial 0.3-mthick sections of the IEL were captured with a ϫ63 objective zoom 2, and the images were stored for further analysis. The same segment was then washed in PSS and stained with the nuclear dye DAPI (1:500 from stock solution 5 mg/ml), mounted again in the same way as described above, and viewed with the confocal microscope at excitation 405 nm/emission 410 -475 nm to visualize cell nuclei. Image capturing was as follows. From each artery, a single image was captured in the midpoint of the artery with a ϫ20 objective. In addition, three randomly selected regions were visualized with a ϫ63 objective zoom 2. In each of these regions, stacks of 1-m-thick serial optical sections were captured from the first visible adventitial cell nuclei to the first visible endothelial cell nuclei. An additional group of images focusing on the endothelial monolayer were captured along the entire segment length.
Quantitative analysis of confocal data. Quantitative analysis was performed with Metamorph image analysis software (Universal Imaging). The relative area occupied by elastin vs. fenestrae was quantified in binary images obtained from reconstructions derived from the serial optical sections of the IEL.
The quantification of the number of the different cells and the thickness of each layer is based on the differences in the shape and orientation of the nuclei of the adventitial, VSMC, and endothelial cells and the capacity of the confocal microscope to obtain serial optical sections of defined thickness (5, 6, 8) . The artery thickness is given (in m) by the number of planes between the first image showing an adventitial cell and the last image showing an endothelial cell at their maximum intensities (5) . Based on the differences in shape and orientation of the cell nuclei, adventitia and medial layer thickness can also be quantified in a similar way. Adventitial and VSMC are counted in a certain volume, defined by the image area (13,867 m 2 , for a ϫ63 objective zoom 2) and the layer thickness of each particular vessel. As stated above, three different regions were averaged per vessel, and the cell number was referred to 1 mm length artery. Endothelial cells are quantified in several single images obtained along the arterial length and calculated per area, since endothelium is a monolayer. Data are expressed as endothelial cell number per luminal surface area of each vessel, which was calculated from the internal diameter measured from images captured with the ϫ20 objective.
Confocal microscopy study of NO and superoxide anion. NO availability was studied with the fluorescent indicator 4,5-diaminofluorescein diacetate (DAF2-DA), as described (34) . Briefly, freshly dissected segments were stabilized in eppendorff tubes in oxygenated PSS (30 min, 37°C). Thereafter, the segments were incubated in oxygenated PSS containing 10 mol/l DAF2-DA for 30 min in the darkness at 37°C in a shaking bath. Finally, the segments were washed three times for 1 min in PSS and fixed in 4% PFA. The segments were then mounted in fluoroguard and visualized with the confocal microscope with a ϫ63 oil objective zoom 2 using the excitation 488 nm/emission 515 nm line. Three randomly selected regions of the medial layer were captured in each vessel with a ϫ63 objective (262,144 m 2 ). In each region, 1-m-thick serial optical sections (20 in total) were acquired at identical conditions of brightness, contrast, and laser power for all experimental groups. Quantitative analysis was based on the fact that NO is directly proportional to the level of fluorescence intensity produced by DAF2-DA, which is incorporated in the cell cytoplasm (34) . For each region, a confocal projection of 20 m of the medial layer was created with Metamorph image analysis software, and fluorescence intensity was quantified in these projections.
The fluorescent indicator dihydroethidium (DHE) was used to determine basal superoxide anion availability (34) . The protocol was similar to the one described above, substituting DAF2-DA for 3 mol/l DHE and counterstaining the nuclei with DAPI. Three randomly located regions of the medial artery were visualized with a ϫ63 objective zoom 2, using the excitation 488 nm/emission 590 -620 nm line to locate DHE and the excitation 405/emission 410 -475 nm wavelength to visualize DAPI-stained cells. In each region, 1-mthick serial optical sections (20 m in total) were acquired at identical conditions of brightness, contrast, and laser power for all experimental groups. DHE fluorescence is located in the nucleus, and the level of superoxide anion is directly proportional to the number of DHEpositive cells. The number of DHE-positive cells was counted in a fixed volume, determined by the area of image at ϫ63 zoom 2 and in 20-m z sections (13,867 m 2 ϫ 20 m), and then referred to 1-mm-length vessel.
Determination of collagen fiber content. Collagen fiber content was assessed in transverse sections from MRA segments embedded in OCT compound (Gentaur) and kept frozen. Rings (5 m thick) were cut with a cryostat and stained with sirius red. The samples were observed under polarized light using a light microscope (Leica DMBL; Germany) equipped with a polarizer/analyzer set, as described previously (19, 40) . From each artery, several rings were imaged with phase contrast and with polarized light to determine artery size and collagen fiber content, respectively. Polarized light images were subsequently transformed in binary images with Metamorph image analysis software. Collagen fiber content was then quantified as the collagen area relative to wall area.
IMA Structure and Composition
Whole paraffin-embedded hearts were used to assess the geometry and composition (cells and collagen) of IMA (Ͻ150 m internal diameter). Transverse 10-m-thick sections were cut from the midpart of the ventricles and set on slides. The sections were deparaffinated with xylol, followed by serial alcohols and distilled water. Thereafter, the heart sections were stained with sirius red. Collagen was visualized as described above for MRA and quantified relative to lumen area. DAPI-stained sections were visualized with a spectral confocal microscope (SP2 Leica Microsystems) at excitation 405 nm/emission 410 -475 nm to visualize cell nuclei and at excitation 488 nm/ emission 500 -560 nm to visualize elastin to determine the edges of the vessel. From these images, the internal diameter, wall thickness, and number of cells were quantified. Cell number was expressed relative to the area of the wall.
TTE
TTE studies were performed with an echocardiographic system (Acuson Sequoia C512) equipped with a 13-MHz transducer in accordance with the American Society of Echocardiography guidelines (60) . Briefly, WKY and SHR were anesthetized (4 mg/kg valium and 10 mg/kg ip ketamine), and M-mode imaging of the paraesternal short-axis (papilary level) view allowed measurement of left ventricular mass (LVM) end-diastolic internal diameter (LVIDd), posterior wall thickness at diastole (PWd), and septal wall thickness at diastole (IVSd). The above measurements were used for calculations of LVM (20) . After the TTE was performed, SHR were allowed to recover from anesthesia, and they were subsequently treated with LGF, as described above. After the period of treatment, TTE was performed again. 
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Statistical Analysis
Results are expressed as means Ϯ SE, and "n" denotes the number of animals used in each experiment. Statistical analysis was performed with GraphPad Prism 4 software. One-or two-way ANOVA followed by a Bonferroni post hoc test were used, as appropriate. A value of P Ͻ 0.05 was considered statistically significant.
RESULTS
Blood Pressure and Weights
Rat weight was not statistically different between groups. Intra-arterial SBP and DBP were significantly elevated in SHR compared with WKY control.
LGF treatment significantly reduced SBP and DBP in SHR but had no effect on WKY rats. The heart weight-to-body weight was also significantly larger in SHR compared with WKY rats, and it was significantly reduced in the LGF-SHR group. WKY heart weight was not affected by LGF treatment (Table 1) .
Studies in Cultured VSMC
Cultures of VSMC derived from SHR exhibited a significantly reduced number of BrdU-positive and increased number of binucleated cells compared with VSMC derived from WKY rats ( Table 2 ). Incubation (48 h) with LGF significantly increased the number of BrdU-positive and decreased the number of binucleated VSMC in SHR cultures, whereas LGF incubation had no effect in WKY-derived cultures (Table 2) .
In a second group of experiments, VSMC derived from WKY and SHR were compared with cells derived from treated rats (WKY-LGF and SHR-LGF). VSMC derived from SHR-LGF exhibited a significantly increased number of BrdUpositive cells and a reduced number of binucleated cells compared with cultures derived from untreated SHR counterparts. By contrast, no significant difference was found between cultures derived from WKY-LGF treated and untreated WKY rats (Fig. 1A) . Cultures derived from SHR exhibited increased fibronectin deposition compared with cells derived from WKY rats. VSMC derived from SHR-LGF produced less fibronectin compared with cells from untreated SHR. However, there was no statistical difference between cultures derived from WKY-LGF and untreated WKY rats (Fig. 1B) . VSMC derived from LGF-treated rats did not differ statistically from WKY-derived VSMC in any of the parameters studied (Fig. 1) .
MRA Study
Geometry and mechanics. Figure 2 shows the geometric parameters of MRA from WKY, SHR, and SHR-LGF mounted on a pressure myograph and measured under fully relaxed conditions from 3 to 140 mmHg. At the entire range of pressures, internal diameter was significantly reduced in SHR compared with WKY, the wall thickness and wall-to-lumen ratio were significantly higher in SHR, and the wall CSA was similar between strains.
LGF treatment did not modify vessel geometry.
Incremental distensibility was significantly reduced in SHR only at low pressure values (20 and 40 mmHg), and LGF treatment significantly increased those values (Fig. 3A) . MRA from SHR also exhibited an increased intrinsic stiffness, as shown by the leftward shift of the stress-strain relationship and significantly larger ␤Ϫvalue compared with WKY.
LGF treatment shifted the stress-strain relationship toward the right and significantly reduced ␤Ϫvalues compared with SHR (Fig. 3B) . ␤ϪValues from LGF-SHR and WKY did not differ statistically.
Wall composition. Adventitial and medial thickness were quantified with confocal microscopy in MRA segments pressurized at 70 mmHg. Compared with WKY rats, total wall thickness was significantly increased in SHR because of an increase in both adventitia and media layers. LGF treatment did not modify layer thickness (Fig. 4A) . There was no statistical difference in adventitial cell density among the three experimental groups. VSMC density was significantly reduced in SHR compared with WKY rats, and it was increased in SHR-LGF compared with SHR (Fig. 4B) . Endothelial cell density was not statistically different between WKY and SHR and was significantly increased by LGF treatment (Fig. 4B) .
The relative area occupied by elastin in the IEL was significantly larger in SHR compared with WKY rats. LGF treatment significantly reduced the relative area occupied by elastin (Fig. 5A) . Sirius red staining and polarized light showed only red staining, whereas green birefringence was not observed in any of the preparations, indicative of the presence of mature collagen type I fibers. The relative area occupied by collagen fibers in the arterial wall was significantly increased in SHR vessels compared with WKY.
LGF treatment significantly reduced collagen fiber content (Fig. 5B) . Elastin and collagen contents in SHR-LGF MRA did not differ statistically from those found in WKY rats.
Vasodilator function. Effective lumen diameter at 0.9L 100 was significantly smaller in MRA from SHR compared with WKY counterparts, and it was significantly increased in SHR-LGF (Fig. 6A) . KCl contractions were not statistically different between WKY (2.3 Ϯ 0.2 mN/mm), SHR (2.6 Ϯ 0.13 mN/ mm), and SHR-LGF (2.9 Ϯ 0.15 mN/mm). The concentrationresponse curve to the endothelium-independent vasodilator SNP (10 Ϫ9 to 10 Ϫ4 mol/l) was not different between the three experimental groups (data not shown). Maximal dilatation to SNP was 98.5 Ϯ 1% in WKY, 97.9 Ϯ 1% in SHR, and 93.3 Ϯ 6% in SHR-LGF.
In WKY rats, ACh elicited a concentration-dependent relaxation at all concentrations tested, whereas, in SHR, ACh elicited a biphasic response with dilatation at low concentrations (10 Ϫ9 to 10 Ϫ7 mol/l) and contractions at higher concentrations (10 Ϫ6 and 10 Ϫ5 mol/l).
LGF treatment did not modify the pattern of ACh responses (Fig. 6B) . AUC for the concentrations 10 Ϫ9 to 10 Ϫ7 mol/l was similar between the three experimental groups (AUC WKY ϭ 119.6 Ϯ 4.6; AUC SHR ϭ 109.8 Ϯ 5.9; AUC SHR-LGF ϭ 100.6 Ϯ 5.7).
The NOS inhibitor L-NAME reduced ACh relaxations in the three experimental groups (Fig. 6C) . To compare the effect of L-NAME among the three experimental groups, avoiding the contribution of the vasoconstrictor factor that is present in SHR and SHR-LGF but not in WKY vessels, we calculated the AUC for the concentrations 10 Ϫ9 to 10 Ϫ7 mol/l. AUC was significantly larger in SHR compared with WKY (AUC WKY ϭ 10.3 Ϯ 2.0; AUC SHR ϭ 44.3 Ϯ 8.6, P Ͻ 0.05), which indicated that L-NAME was less effective in blocking ACh relaxations in SHR. AUC was significantly reduced in LGF-SHR (AUC SHR-LGF ϭ 20.0 Ϯ 2.9; P Ͻ 0.05 compared with SHR). EC 50 values also indicated that SHR MRA relaxed at a lower concentration in the presence of L-NAME compared with WKY rats (WKY ϭ Ϫ6.3 Ϯ 0.08; SHR ϭ Ϫ7.2 Ϯ 0.2; P Ͻ 0.05); LGF treatment also reversed this effect (SHR-LGF ϭ Ϫ6.3 Ϯ 0.2; P Ͻ 0.05 compared with SHR).
The inhibition of EDHF by 40 mmol/l KCl significantly reduced ACh relaxations in the three experimental groups (Fig.  6D ). Under these experimental conditions, the AUC for the concentrations 10 Simultaneous inhibition of NO and EDHF by L-NAME and 40 mmol/l KCl practically abolished ACh-induced vasodilata- 
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Basal NO and superoxide anion. The fluorescence emitted by the NO indicator DAF2-DA was located in VSMC cytoplasm. DAF2-DA average fluorescence intensity was significantly smaller in MRA from SHR when compared with WKY, and it was significantly increased in SHR-LGF compared with SHR (Fig. 7A) .
The fluorescence emitted by the superoxide anion indicator DHE was located in the cell nuclei. The number of DHEpositive cells was significantly increased in the medial layer in SHR compared with WKY, and it was significantly decreased in SHR-LGF compared with SHR (Fig. 7B ).
Heart and IMA Study IMA structure. In SHR, IMA lumen size was significantly smaller while the wall thickness and wall-to-lumen ratio were larger compared with WKY counterparts. LGF treatment did not modify wall thickness or lumen size but significantly reduced the wall-to-lumen ratio (Fig. 8A) . Perivascular collagen was significantly increased, whereas cell number was decreased in SHR arteries compared with WKY. LGF treatment normalized both parameters to levels not significantly different from WKY rats (Fig. 8B) .
Echocardiographic study. Compared with WKY, SHR exhibited a significantly larger LVM, IVSd, and PWd and a reduced LVIDd. LGF treatment produced a significant increase in LVIDd and reduced IVSd and LVM compared with the SHR before treatment (Table 3) .
DISCUSSION
In our previous study, we described the antihypertensive actions of short treatment with LGF and the specificity of this factor on the hypertensive strain, with no hemodynamic or vascular effects on WKY rats (62) . This was further confirmed in the present study showing a significant reduction of blood pressure induced by treatment in SHR, which was not observed in the normotensive WKY rat. As in our previous study, we used 4.5 g LGF/rat in four injections over a period of 12 days. The rationale for the use of this dose and time of administration is based on the actions of LGF as mitogen in liver, which has been extensively analyzed. In these studies, different LGF doses were injected in rats to determine the dose producing the greatest liver DNA synthesis stimulation, which was established in 4.5 g/rat (26) . Regarding the duration of treatment, these studies also demonstrated that, upon injection in rats,
LGF produces a maximum liver DNA and protein synthesis at 24 and 48 h, respectively, declining by the 3rd and 4th day after injection (26) . Based on this pattern of 3-to 4-day activity, the first experimental protocols to study the regenerative actions of the factor in liver disease were designed with four injections with a delay of 3 days between them. This treatment proved to be effective in blood pressure reduction in SHR in our previous study (62) and also in other diseases, such as testicular degeneration (51), lung fibrosis (47), and atherosclerosis (65) .
Regarding the mechanism by which LGF produces its antihypertensive effect in SHR, there are two possibilities: a reduction in cardiac output and/or in total peripheral resistance. Increased peripheral resistance is a characteristic feature of hypertension. As an adaptation to the increased work load imposed by a high peripheral resistance, LVH also takes place. In SHR, it has been described that, at initial stages, heart hypertrophy produces an increase in cardiac output, but, as time progresses, in adult rats, cardiac output decreases to levels similar to WKY (28, 61) . Finally, in aged rats, it is further reduced in association with heart failure (10). LGF treatment reduced both SBP and DBP together with heart weight/body weight in SHR but had no effect in WKY rats, suggesting that both vascular and cardiac effects of LGF are specific of SHR. In paired experiments, we confirmed with echocardiography the partial regression of LVH in SHR by LGF treatment, which normalized telediastolic chamber size and reduced the LVM. Moreover, LGF was also able to improve the alterations in Fig. 2 . Internal diameter, wall thickness, cross-sectional area (CSA), and wall-to-lumen ratio-pressure curves in fully relaxed mesenteric resistance artery (MRA) segments of WKY, SHR, and SHR-LGF, determined with pressure myography. Data are expressed as means Ϯ SE. The no. of segments is shown in parentheses, and n denotes the no. of rats. Statistical analysis was performed by 2-way ANOVA. ϩP Ͻ 0.05, SHR compared with WKY.
SHR IMA structure, which is characterized by vessel narrowing, hypertrophy, perivascular fibrosis, and reduced vascularization (29, 44) . LGF treatment produced a significant reduction of the wall-to-lumen ratio, together with a normalization of the excessive perivascular collagen and the reduced VSMC number observed in SHR. In view of the importance of restoring the vascular element in hypertensive LVH (59), these effect of LGF on heart and heart vessels supports the therapeutic potential of LGF to prevent the development of adverse cardiovascular events in hypertension.
Under our experimental conditions, echocardiographic data did not allow separating the early diastolic filling wave and late filling wave of transmitral flow. This problem had been previously reported (42) and prevented us from determining diastolic function. Although we could not measure cardiac output, the normalization of telediastolic left ventricular diameter and the improvement of intramyocardial vasculature support that heart function is probably improved by treatment. With these data, we suggest that cardiac output is unlikely decreased and the reduction of blood pressure induced by treatment is probably associated with a reduction in peripheral resistance. The elevations of SBP and DBP in hypertension are linked to large artery stiffening and resistance artery remodeling, respectively.
The reduction of both parameters by LGF treatment indicates that, in addition to an improvement in conduit arteries, as shown in our previous study (62) , LGF is able to exert effects on resistance vessels.
It is well known that total peripheral resistance is increased in SHR from a young age (28) , as a result of resistance artery remodeling and impaired vasodilatation. These alterations are also linked to a higher risk of cardiovascular adverse events (48, 55) . Therefore, we found of interest to study the effects of LGF treatment on resistance vessel structure and function, using third-order branches of mesenteric bed (MRA), a classical vessel to assess resistance artery remodeling. As previously described by us and others (13, 39, 45) , compared with WKY rats, SHR MRA exhibited eutrophic inward remodeling, characterized by reduced lumen size and increased wall thickness and wall-to-lumen ratio without changes in wall CSA at the entire range of pressures. Confocal microscopy showed that both adventitia and media layers contributed to the increased wall thickness in SHR arteries. Mechanical parameters were also assessed at the entire range of pressures and, as previously described (13, 39, 45) , SHR MRA exhibited reduced distensi- bility only at low pressures. This phenomenon has been suggested to result from changes in artery geometry (45) , probably because of the fact that the increments in lumen diameter with intraluminal pressure are more pronounced at pressures below 60 mmHg. We have also suggested that the reduction of SHR distensibility at low pressure might be related to the alterations in elastin, since this is the range of pressures where this protein is operative (13) . In SHR, there was a leftward shift of the stress-strain curve and a significant increase in the ␤-value, indicative of elevated intrinsic stiffness of the wall material Ϫ4 mmol/l L-NAME. Relaxation was expressed as % of the previous tone with 10 Ϫ7 mol/l NE or 40 mmol/l KCl. Data are expressed as means Ϯ SE. The no. of segments is shown in parentheses, and n denotes the no. of rats. Statistical analysis was performed by 2-way ANOVA. P Ͻ 0.05, SHR compared with WKY (ϩ) and SHR-LGF compared with SHR (*).
independent of geometry (13, 39) . LGF treatment did not have an effect on resistance artery geometry, but it normalized ␤Ϫvalues. Because this parameter was measured under conditions of deactivated VSMC, we suggest that treatment modifies ECM components. Excessive collagen is well known to contribute to the rigidity of the arterial wall of resistance arteries in hypertension (12, 13, 54) . This increase in MRA collagen content in SHR was confirmed in the present study. Under polarized light conditions, only red color was observed in the MRA preparations, suggesting the presence of mature collagen type I fibers and the absence of loosely packed collagen (19) or thinner type III fibers, characterized by yellow-green birefringence (54). As discussed above for IMA, the increased collagen content observed in SHR MRA was normalized by LGF treatment to levels not different from those found in WKY MRA.
LGF treatment also normalized the elevated elastin levels found in SHR MRA. Elastin content has been previously shown to be increased in SHR conduit (4, 29) and resistance arteries (13, 33) and, despite the fact that it is the protein that provides blood vessels with resilience and elasticity, we have previously demonstrated that excessive and aberrant deposition of elastin contributes to the elevated intrinsic stiffness in SHR aorta (4) and MRA (13) . In addition to collagen and elastin, nonfibrous proteins such as fibronectin (key for cell-matrix attachments) have been implicated in vascular stiffening in hypertension (39) . We have previously reported an increase in MRA segments were stained with the fluorescent indicators DAF2-DA (NO; 488 nm/500 -560 nm) or DHE (superoxide anion; 488 nm/590 -620 nm) and visualized with a laser-scanning fluorescence confocal microscope. All images were obtained under identical conditions of laser power, intensity, and gain. Quantification was obtained with Metamorph image analysis software. Data are expressed as means Ϯ SE. The no. of segments is shown in parentheses, and n denotes the no. of rats. P Ͻ 0.05, SHR compared with WKY (ϩ) and SHR-LGF compared with SHR (*). Fig. 8 . Gross structural parameters (A) and perivascular collagen fiber and cell content (B) in intramyocardial arteries from WKY, SHR, and SHR-LGF. Sections (10 m thick) of the hearts were stained with sirius red or DAPI and visualized with a Leica DMBL or a Leica confocal microscope, respectively. Quantification was obtained with Metamorph image analysis software. Data are expressed as means Ϯ SE. The no. of rings is shown in parentheses, and n denotes the no. of rats. P Ͻ 0.05, SHR compared with WKY (ϩ) and SHR-LGF compared with SHR (*). fibronectin in carotid arteries from a SHR-stroke prone rat (11) as well as in VSMC cultures derived from SHR (7). The increased fibronectin deposition by VSMC cultures was confirmed in the present study, which also demonstrated a reduction by LGF treatment, again specific to the hypertensive strain. Taking together these data, in SHR, there is a parallel increase in several ECM proteins that contribute to vascular stiffening, and LGF treatment was able to normalize all of them to levels not different from those found in the WKY normotensive strain. ECM normalization was found in carotid arteries in our previous study (62) and now confirmed in MRA and IMA.
We suggest that the reduction of excessive vascular ECM production in SHR might be linked to the mitogenic actions of LGF for the following reasons. We have previously demonstrated that the excessive ECM deposition by VSMC from SHR is related to a cellular defect in SHR, consisting of defective proliferation, but enhanced cell survival of hypertrophied diploid cells, which keep producing ECM, without normal turnover (7) . On the other hand, the regenerative actions of LGF in several biological systems have been linked to its mitogenic effects (26, 27, 35, 52) . In our previous study, we also reported that LGF was able to improve the reduced VSMC density and abnormally high ploidy in carotid arteries from SHR. We further confirmed these actions of LGF in cultured VSMC. In fact, LGF, both in vitro and as treatment, was able to completely normalize proliferation and ploidy in parallel with decreased ECM deposition. Because VSMC from SHR are arrested at the G2 ϩ M phase of the cell cycle (63), we speculate that LGF might help the cellular progression through the cell cycle. The hypothesis that LGF is a mitogen for VSMC is also suggested by the normalization of VSMC density in resistance vessels from SHR-treated rats. In both MRA and IMA from SHR, we found a lower density of VSMC, as previously demonstrated in MRA from SHR-stroke prone rats (8) . In contrast, adventitial cell density was not elevated in SHR, as previously observed in SHR-stroke prone rats, a difference that might be attributed to the higher severity of hypertension in the SHR-stroke prone model, possibly involving inflammatory processes.
LGF was also able to increase endothelial cell number, as previously described in intraparenquimal cerebral vessels from rats treated with LGF (35) . All these data suggest that LGF acts as mitogen for vascular cells, and it is able to normalize the imbalance between decreased cell number-excessive ECM production in the vascular wall. It is worth mentioning that LGF treatment of WKY rats did not have any effect on proliferation, ploidy, or ECM deposition, which suggests that LGF treatment does not produce indiscriminate cellular proliferation in healthy tissues. This has been previously demonstrated by time course experiments treating healthy rats with LGF, where an initial increase in hepatocyte number was gradually eliminated without disturbing organ homeostasis (27) .
In addition to the geometric and mechanical alterations of MRA from SHR, these vessels also exhibit endothelial dysfunction. This was confirmed in the present study showing a reduced effective lumen diameter of SHR MRA, which indicates an increased basal tone, probably because of a reduced basal availability of endothelial vasodilator factors. Effective lumen diameter was normalized by LGF treatment; therefore, we explored the possible effect of LGF on endothelial function by the ACh test. Under our experimental conditions, MRA from SHR exhibited a biphasic response to ACh, whereas in WKY only a vasodilator component was observed. The contractile component was maintained after NO and EDHF blockade and has been previously demonstrated to be due to the effect of cyclooxygenase (COX)-derived prostanoids and/or free radicals released at high concentrations of ACh in SHR MRA, which are not produced in the WKY strain (2, 30, 69) .
LGF treatment did not have an effect on the contractile component of the ACh concentration-response curve, suggesting that LGF does not modify the COX-derived prostanoid. Regarding the vasodilator component, the two main factors implicated in resistance arteries are NO and EDHF (2), and their relative contribution can be studied by the blockade induced by the NOS inhibitor L-NAME (50) or in vessels precontracted with 40 mmol/l KCl, which inhibits EDHF (50) . This was confirmed in our study by the abolition of ACh vasodilatation in the three experimental groups by simultaneous blockade with L-NAME and 40 mmol/l KCl. Our results also indicate that the inhibition caused by L-NAME was smaller in SHR compared with WKY, indicative of a reduced NO-mediated relaxation in the hypertensive strain.
LGF treatment improved NO-dependent but not an EDHF-mediated component, in accordance with the increased NO availability and reduction of superoxide anion levels detected with the fluorescent-probes DAF2-DA and DHE. These data are similar to those previously reported in MRA from SHR treated with L-carnitine and propionyl-L-carnitine where the improvement of NO-mediated relaxation was associated with increased NO availability via an antioxidant action (2), suggesting that LGF might exert at least part of its actions through an antioxidant mechanism (see below).
Possible Mechanism of Action of LGF
We did not explore in detail the mechanism of action of LGF. However, the present and previous data let us suggest that it can be linked to an antioxidant effect. First, LGF was able to reduce the elevated superoxide anion levels in SHR MRA, which is a common feature in several vascular beds from SHR (2, 34) . We have previously demonstrated that LGF exerts potent in vitro scavenging capacity against several ROS, including superoxide anion and hydroxyl and peroxyl radicals (18) . The antioxidant capacity of LGF can be explained by its chemical nature, since LGF is an albumin-bilirubin complex Values are means Ϯ SE; n, no. of rats. Pre-LGF SHR and post-LGF SHR, spontaneously hypertensive rats before and after LGF treatment, respectively; LVM, left ventricular mass; LVIDd, left ventricular internal diameter at end diastole; IVSd, interventricular septum thickness at diastole; PWd, left ventricular posterior wall thickness at diastole. P Ͻ 0.05 compared with WKY (ϩ) and compared with pre-LGF SHR (*).
and both albumin and bilirubin exert antioxidant and protective actions in the cardiovascular system. For example, albumin itself exhibits free radical-scavenging activities because of several amino acids situated in the outer part of the molecule, like Cys and Met (56) , and human serum albumin is able to reduce circulating and tissue superoxide anion levels, improving endothelial dysfunction (49) . Regarding bilirubin actions, exogenous administration in very low concentrations, in the nanomolar range, is able to restore myocardial function and to reduce infarct size after reperfusion (16) , and the inhibition by bilirubin of vascular endothelial cell activation and dysfunction is responsible for the antiatherogenic properties of heme oxygenase-1 (41) . Moreover, antioxidant protective effects for noncovalent complexes between albumin and bilirubin similar to LGF have been previously reported in hepatocytes, erythrocytes, and myocytes (64, 72) . Because vascular fibrosis and endothelial dysfunction in the SHR model are linked to oxidative stress (66) , an antioxidant mechanism of action of LGF could explain both the improvement of NO availability and the antifibrotic effects. In fact, several antihypertensive treatments are able to reduce vascular remodeling and ECM alterations in SHR through a ROS scavenging mechanism (14, 70) . The effects of LGF resemble the actions of melatonin administration, another endogenous antioxidant, which was not able to reduce LVH but reduced oxidative damage, resulting in an attenuation of left ventricular fibrosis (53) . Taken together, these data suggest that a possible mechanism of action of LGF is through an antioxidant effect.
Regarding the mode of signaling to cells, we suggest that LGF might act through binding to cell surface receptors on endothelial cells. There are receptors for ''modified albumins'' (albumin with ligand bonds) in endothelial cells, such as the albumin-binding receptors Gp30, Gp18, and GP60 (58), some of them present in caveolae mediating transcytosis (67) . The possibility that LGF could internalize and signal in the endothelium, despite its large size, is also supported by the recently discovered effect of LGF activity in Parkinson's diseases after intraperitoneal injection (36) .
Limitations of the Study
The present data demonstrate the quick antihypertensive, antifibrotic, and regenerative actions of LGF in several vascular beds and the partial reversion of LVH in SHR. We are at the initial steps of study of the cardiovascular actions of LGF; therefore, many questions remain unanswered. The first is the duration of the cardiovascular effects after treatment withdrawal. Various long-term and also some short-term antihypertensive treatments have been shown to induce persistent changes in blood pressure and cardiovascular structure weeks after treatment removal (38) . Therefore, an important question that needs to be addressed is whether the withdrawal of LGF treatment would or not maintain the reduction of blood pressure and the regenerative cardiovascular actions. A second limitation of this study is if a higher dose or time of treatment with LGF could have reversed to a higher extent the cardiovascular alterations in SHR. For example, it has been reported that high doses of zofenopril achieved a maximal effect after 4 wk of zofenopril treatment and were maintained over the following 4 wk, an effect that was not observed in the low-dose treatment (32) . We are at initial stages of study of the cardiovascular actions of LGF, and these aspects, which have been largely analyzed in classical antihypertensive treatments, deserve further attention.
Another question is the chicken and egg problem, i.e., does LGF improve vascular structure, which, in turn, reduces blood pressure, or does it reduce blood pressure though a vasodilator mechanism that then restores vascular wall structure and mechanics? In other words, what is the initial mechanism responsible for the blood pressure-lowering effects of this drug. With the data available, we might suggest that the initial effect of LGF is at the level of the wall structure rather than as a vasodilator. First, the improvement of vasodilatation was relatively small and limited to NO compared with the effects on wall composition, which were much marked. In fact, they were completely restored to levels not different from those found in WKY normotensive rats. Second, the actions of LGF in vitro on VSMC were very rapid, in 48 h, a time course effect similar that found in liver (27) and in the striatum (52) , suggesting that the first actions of LGF might be on cell/ECM balance, which in turn has a favorable impact on vascular and heart mechanics, reducing blood pressure. In the study of new antihypertensive treatments, to address the chicken and egg question, it has been common to include a group of animals treated with a general vasodilator, such as hydralazine or hydrochlorothiazide, or a combination of both. Although the main mechanism of blood pressure reduction by these drugs is vasodilatation, some effects on vessel geometry, elastic fibers (29) , and on MRA mechanics (unpublished results) have been reported. It is interesting to note that, despite a complete normalization of blood pressure by a combination of hydralazine (44 mg·kg Ϫ1 ·day Ϫ1 ) and hydrochlorothiazide (9.4 mg/kg) during 12 wk in our SHR colony (3), the effects of these drugs on MRA mechanics were modest (unpublished data). These data suggest that blood pressure-lowering effects on its own do not have such a big impact in MRA wall mechanical properties, supporting the idea that LGF has a mechanism of action other than vasodilatation. In spite of the evidence of a quick effect of LGF on vascular composition, we cannot exclude other possible actions of LGF on blood pressure regulation, particularly at a central level, since there is evidence that LGF is able to act on the central nervous system (52) , and SHR exhibit abnormalities in sympathoexcitatory neurons (15) , hypereactivity of the brain renin-angiotensin-system, and reduced arterial baroreflex function (68) .
We would like to point out the quick actions of LGF treatment and low doses needed to achieve an effect on SHR, which produced similar or larger cardiovascular effects compared with classical antihypertensive treatments, particularly regarding fibrosis, which was completely reversed in the three vascular beds analyzed (conduit, resistance and inramyocardial). For example, 6 wk of 10 mg·kg Ϫ1 ·day Ϫ1 enalapril treatment of SHR improved VSMC phenotypic changes and perivascular collagen but did not modify the wall-to-lumen ratio of IMA (44), whereas LGF was able to improve this parameter. Olmesartan treatment (16 wk) at the same dose was needed to reduce LVH (29) , and 3 mo of daily treatment with zofenopril, also at 10 mg·kg Ϫ1 ·day
Ϫ1
, was able to markedly improve blood pressure, LVH, vascular remodeling, and endothelial dysfunction in SHR, but a lower dose (0.5 mg·kg Ϫ1 ·day Ϫ1 ) had a weaker effect (32) . Furthermore, recently discovered actions of LGF treatment on arteries from apolipoprotein E knockout mice, involving a 25% reduction of atherosclerotic lesions (65) , suggest that LGF has wider cardiovascular regenerative effects.
In summary, the present work demonstrates that LGF treatment has widespread regenerative cardiovascular actions in SHR. It 1) restores normal wall composition in resistance and intramyocardial vessels, 2) reduces LVH, and 3) improves NO availability through a decrease in superoxide anion levels. These effects, together with our previously reported ROS scavenging properties of LGF in vitro (18) , let us suggest that the mechanism of action of LGF might be related to an antioxidant effect. The regenerative actions of LGF in a markedly short time of treatment and low dose make it a potentially interesting molecule in the cardiovascular field.
